Tag: pharmaceuticals

  • Mayo Clinic, Korean Biotech to Collaborate on ALS Research

    Mayo Clinic’s campus in Jacksonville, Florida and SK Biopharmaceuticals in Seoul, South Korea have agreed to develop new treatments for amyotrophic lateral sclerosis (ALS), better known as Lou Gehrig’s disease. The collaboration will center around the work of Mayo Clinic’s Leonard Petrucelli, who heads the neuroscience research department at the Jacksonville campus. ALS results in…

  • Medication Poisoning of Young Children Rising Sharply

    An analysis by researchers at Cincinnati Children’s Hospital Medical Center shows the number of young children hospitalized from a potentially toxic dose of medication has risen markedly in recent years. The findings by Randall Bond and colleagues from Cincinnati Children’s appear online in the Journal of Pediatrics. Bond and his team reviewed more than 453,000…

  • Sanofi Division, Max Planck to Partner on Retinal Research

    Max Planck Society in Germany and Fovea Pharmaceuticals in Paris have agreed to a research and licensing agreement on therapies for restoring vision to patients with diseases affecting the retina. Fovea is the ophthalmology division of the French drug company Sanofi-Aventis. Fovea’s team plans to work with the Max Planck Institute of Biophysics in Frankfurt…

  • Review: Reminder Packaging Can Help Medication Adherence

    A review of studies conducted in the past few years shows instruction reminders on medication packaging helps some patients more closely follow those instructions. The review, led by health sciences professor Kamal Mahtani of Oxford University in the U.K., appears in the current issue of The Cochrane Library (paid subscription required). The analysis by Mahtani…

  • Biotech Developing Anti-Cancer Drugs Gets $15M Investment

    Tensha Therapeutics in Cambridge, Massachusetts says it has received $15 million in early stage financing to advance treatments for cancer by regulating the transcription of disease-associated genes. The series A investment — the first round of funding after a company’s initial seed capital — is provided by HealthCare Ventures, life science venture capital firm, also…

  • Superbug Screening Methods Under Development

    Researchers at University of Houston and St. Luke’s Episcopal Hospital, also in Houston, are developing better screening methods to detect a potentially lethal, drug-resistant superbug found in that region. The team’s findings on the discovery of the multi-drug resistant bacterium appeared earlier this year in the journal Diagnostic Microbiology & Infectious Disease (paid subscription required).…

  • $100K Challenge Seeks Responsive Insulin Delivery

    A new challenge at InnoCentive seeks new ideas for the development of “glucose-responsive insulin” that would respond to the needs of the individual rather than deliver fixed dosage amounts. The competition has a prize of $100,000 and requires a written proposal. The deadline for entries is 9 November 2011. InnoCentive in Waltham, Massachusetts is a…

  • Magnetic Fields Help Purify Hybrid Nanoparticles

    Chemistry, physics, and materials scientists at Pennsylvania State University have invented a new system using magnetism to purify hybrid nanoparticles, a development with implications for drug delivery, medical imaging, and related fields. The findings of Mary Elizabeth Williams,  Raymond E. Schaak, and their colleagues at Penn State appear online in the journal Agewandte Chemie (paid…

  • New Method Can Increase Commercial Antibiotic Yields

    Researchers from the U.K. and Japan have devised a new method for increasing the yields of antibiotic compounds from bacteria. The process, which has practical applications in commercial pharmaceutical production, is scheduled to be described this week in an online issue of the journal Proceedings of the National Academy of Sciences. Most known antibiotics are…

  • Pfizer to Build Research Labs in Cambridge, Mass.

    Pfizer Inc., the global pharmaceutical company based in New York, says it will build a new research facility in Cambridge, Massachusetts. The company expects the facility will employ a staff of 400, most in research or related positions. The new building will be located in Kendall Square, just north of the MIT campus. Pfizer says…